Leukemia News

The FDA granted accelerated approval to ponatinib with chemotherapy for the treatment of adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia, according to a press release.

Scott A. Armstrong, MD, PhD, has been named senior vice president for drug discovery and chief research strategy officer at Dana-Farber Cancer Institute, according to a press release.

The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of certain patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Researchers at Mayo Clinic have identified clinical factors associated with increased risk for developing myeloid neoplasms following chimeric antigen receptor T-cell therapy, according to data published in JAMA Oncology.

Regardless of vaccination status, individuals with hematologic malignancies had increased odds of developing severe COVID-19 until oral antivirals became widely available in mid-2022, according to data published in JAMA Network Open.

Patients with post-transplant relapsed B-cell acute lymphoblastic leukemia who received chimeric antigen receptor T-cell therapy had superior outcomes compared with alternative approaches, study results showed.

Arya Amini, MD, still remembers sitting on the steps outside of his dean’s office at University of California, Irvine, more than a decade ago, prepared to race inside in case he did not get matched with a radiation oncology residency.

The FDA approved inotuzumab ozogamicin for use in pediatric patients with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia, according to a press release.

Liquid biopsy could provide enhanced information about chimeric antigen receptor T-cell therapy compared with normally used DNA, RNA and protein assays, according to findings published in Journal for ImmunoTherapy of Cancer.

Nearly one-half of adults with relapsed or refractory CD19-positive B-cell malignancies responded to treatment with a novel cord blood-derived natural killer cell therapy expressing a chimeric antigen receptor, study results showed.